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Edited by Horst FeldmannAbstract Previously, we described two RNA structural motifs
in the hepatitis C viral (HCV) genome that can be processed in
vitro by human ribonuclease P (RNase P) enzyme [J. Biol.
Chem. 277 (2002) 30606]. One of these structures is located in
the internal ribosome entry site and is conserved in the related
animal pestiviruses [J. Biol. Chem. 278 (2003) 26844]. Here, we
tested two prokaryotic RNase P ribozymes (P RNA) against this
conserved structural motif. In vitro experiments indicated that P
RNA from Synechocystis sp. can speciﬁcally process the viral
transcript preparations in a position close to the human RNase P
cleavage site. This provides additional support for the presence of
an RNA structure similar to tRNA near the AUG start codon
and suggests that Synechocystis P RNA may be an active agent
for HCV antigenomic interventions.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Ribonuclease P1. Introduction
Hepatitis C virus (HCV) is an enveloped virus classiﬁed in
the Flaviviridae family. The genome consists of a single, 9600-
nt non-segmented strand of RNA with a plus polarity. The
genome comprises a 50 untranslated region (50 NCR), which
functions as an internal ribosome entry site (IRES), a long
open reading frame that encodes a polyprotein precursor of
about 3010 amino acids, and a 30 untranslated region [3].
It has been estimated that more than 1% of the world
population is infected with HCV. The virus establishes a
chronic infection in up to 85% of cases. HCV infection has
become the most common cause of hepatocellular carcinoma
and is the primary reason for liver transplantation among
adults in Western countries [4]. Currently, there is no vaccine
for HCV infection, and the only therapy for chronic hepatitis
C is not completely eﬀective, very expensive and has important
adverse eﬀects. Improved treatment for chronic HCV is clearly
needed.* Corresponding author. Fax: +34934894032.
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doi:10.1016/j.febslet.2004.10.059The use of RNA molecules as therapeutic agents is receiving
increasing attention and among these are the ribozymes. The
capacity of ribozymes to speciﬁcally inactivate other RNAs
makes them potentially valuable tools for gene therapy against
HCV. Up to now, hammerhead and hairpin ribozymes have
been used, almost always against the 50 NCR of HCV (the
most highly conserved among the diﬀerent isolates) in a se-
quence-speciﬁc manner (reviewed in[5]). Any approach di-
rected to improve HCV therapy must deal with the high
sequence variability of the viral genome that allows the virus to
escape treatment attempts.
We have focused on developing an antigenomic strategy
directed against RNA viral structures instead of viral se-
quences. The basis for this approach resides in the concept that
although the viral genome undergoes mutations, its functional
structures are theoretically more conserved [6] and, therefore,
remain susceptible to treatment.
Ribonuclease P (RNase P) is a ubiquitous enzyme present in
the three domains of life: Archaea, Bacteria and Eukarya [7].
RNase P recognizes and cleaves the 50 end of all the various
species of pre-tRNA present in cells [8]. But this is not the only
substrate of RNase P; several other natural and artiﬁcial
substrates have been identiﬁed. In Escherichia coli, RNase P
can process RNAs, such as the precursors to 4.5 S RNA [9],
tmRNA [10], a polycistronic pre-mRNA [11] and a small
phage RNA [12]. Thus, this enzyme has evolved to recognize
and process various substrates. This enzymatic plasticity has
proved to be useful for identifying tRNA-like structures in
divergent viral genomes [2,13].
In bacteria, the RNase P enzyme is composed of an RNA
subunit (P RNA) and a protein subunit. The RNA subunit is
the catalytic component; it can cleave substrates in the absence
of the protein [14].
In a previous study, we described two tRNA-like structures
in the ﬁrst one-third of the viral genome that can be speciﬁcally
cleaved by human RNase P [1]. One of these structures, located
in the 50 region of the viral genome, was found to be conserved
in the genomes of viral isolates from diﬀerent patients (Piron
et al., unpublished results), and even in related animal pestiv-
iruses [2]. Therefore, it can be considered a highly conserved
structural element.
The presence of these structural motifs in the HCV genome
opens the door to new antiviral strategies with RNA ribo-
zymes that recognize tRNA-like molecules, e.g., bacterial
RNase P ribozymes. In this study, we tested the ribozymes
from E. coli and Synechocystis sp.ation of European Biochemical Societies.
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cuts the HCV genome in the IRES of the virus in vitro and it
does so in a position very close to where cleavage of the human
enzyme maps.Fig. 1. Activity of P RNA from E. coli and Synechocystis in a cleavage
reaction over an HCV transcript. SI is an HCV BlpI 570 transcript
containing the 50 NCR and the beginning of the core region of the
HCV genome. SII is a 400-nt unrelated RNA corresponding to hepa-
titis B virus (HBV) surface antigen mRNA. As a positive control, pre-
tRNA was used. (A) Autoradiogram of the E. coli P RNA assay of
cleavage of SI and pre-tRNA substrates (1.8 nM). Lanes 1 and 2
represent the control reaction in the absence of ribozyme. Lanes 3 and
4 represent the reaction in the presence of ribozyme (1.8nM). (B)
Autoradiogram of cyanobacterial P RNA cleavage of SI, SII and pre-
tRNA substrates (1.8 nM). Lanes 1, 2 and 3 represent the control
reaction in the absence of ribozyme. Lanes 4, 5 and 6 represent the
reaction in the presence of ribozyme (67.5 nM).2. Materials and methods
2.1. Preparation of ribozymes and RNA substrates
The RNA transcripts used as substrates in the cleavage assays
were derived from the following: plasmids pN (1–4728) Bluescript,
containing nt 1 to 4728 of hepatitis C virus under the T7 promoter;
a pUC18, containing a PCR product which includes the T7 pro-
moter+ the HCV sequence from nucleotides 1 to 418 followed by
an exogenous EcoRI DNA cleavage site; a pUC19 TyrT, containing
the sequence of the naturally occurring precursor to tRNATyr; and
a plasmid containing a 400-nt unrelated RNA corresponding to
hepatitis B virus (HBV) surface antigen mRNA. Uniformly labeled
RNA substrates were obtained by in vitro transcription of 1–2-lg
DNA templates (1 h at 37 C) in the presence of [a-32P]GTP or [a-
32P]ATP followed by treatment with RNase-free DNase I for 5-min
at 37 C. Cellulose CF11 chromatography was used to eliminate
DNA fragments and non-incorporated nucleotides. Transcripts were
then puriﬁed by gel electrophoresis under denaturing conditions on
4% polyacrylamide gels containing 7 M urea. Bands were visualized
by autoradiography, excised from the gel and eluted in T1 buﬀer
(100 mM Tris–HCl, pH 7.5, and 10 mM EDTA, pH 7.5). The
concentration of radioactive transcripts was determined by calcu-
lating the amount of incorporated [a-32P]NTP based on scintillation
counting. In order to obtain 30 end labeled transcripts, uniformly
labeled and unlabeled RNAs were both transcribed, run in parallel
and bands were eluted from acrylamide gel. The ‘‘cold’’ transcript
was subsequently labeled with T4 RNA ligase and [32P]pCp 50
triphosphate under conditions similar to those described by the
manufacturer. The reaction was carried out in 30 lL of 50 mM
Tris–HCl, pH 7.5, 10 mM MgCl2, 10 mM DTT, 1 mM ATP,
0.01% BSA, and 10% DMSO. The reaction mixture was incubated
overnight (12–15 h) at 4 C. The labeled RNA was puriﬁed again
using the electrophoretic procedure described above. For the 50
end labeled transcripts preparations, ‘‘cold’’ transcripts prepared as
before were labeled with [a-32P]GTP and the enzyme guanylyl
transferase.
pFL117 and pT76803 were used as DNA templates for the T7-de-
pendent runoﬀ transcription of E. coli P RNA and Synechocystis sp.
PCC6803 RNase P RNA, respectively. An unlabeled and a uniformly
labeled transcription were done in parallel and gel puriﬁed. The
amount of isotopically labeled RNA enzyme was measured in a scin-
tillation counter and it was estimated that the yield of recovery of
unlabeled RNA enzyme was equivalent. Unlabeled ribozymes were
used in the cleavage assays. Diﬀerent puriﬁcation of the ribozymes
gave identical results.
2.2. Cleavage assays
For the M1 cleavage assays, re-natured ribozyme (1.8 nM) was
incubated with substrate transcripts (1.8 nM) in a volume of 10 lL
for 60 min at 37 C in 50 mM Tris–HCl, pH 7.5, 100 mM NH4Cl,
100 mM MgCl2 and 4% (wt/vol) polyethylene glycol. For the cy-
anobacterial P RNA assays, varying amounts of the ribozyme were
incubated in assay buﬀer (50 mM Tris–HCl, pH 7.5, 100 mM
MgCl2, and 1 M KCl) for 15 min at 37 C before addition of the
substrate (1.8 nM). Ionic conditions have been obtained from pre-
vious work of Pascual and Vioque in [17]. In the present study, ti-
tration of Mg2þ concentrations from 10 to 100 nM revealed that
cleavage of tRNA precursor and HCV RNA starts at 50 nM and
increases at 100 nM (data not shown), in agreement with previously
mentioned authors.
Reactions were stopped by addition of 2 volumes of gel loading
buﬀer. Cleavage products were separated on denaturing polyacryl-
amide gels and visualized by autoradiography.
2.3. Partial and total T1 nuclease digestion of RNA
For partial RNase T1 reaction, the digestion mixture (10 lL)
contained about 2 104 Cerenkov cpm of the 30 end labeled tran-script and 2.5 lg tRNA of carrier in T1 buﬀer. The cleavage reac-
tion was initiated by addition of 0.001 lg nuclease T1, incubated at
37 C for 20 min. The reaction was stopped by addition of 2 vol-
umes of gel loading buﬀer and products were resolved on 8% de-
naturing polyacrylamide gel. For total RNase T1 digestion, similar
conditions were employed, but the amount of nuclease in the reac-
tion was 1lg/ll ﬁnal concentration, and the products were run in
20% denaturing polyacrylamide gel. Gels were visualized by auto-
radiography.
2.4. Nucleotide sequence accession number of type 1b and HCV variants
The nucleotide sequence for the ‘‘type 1b’’ HCV genome used here is
available in the GenBank data base under Accession No. S62220.
The nucleotide sequence for HCV variants, var1, var 2, and var 3,
presented in this article can be accessed through EMBL data base
under EMBL data base Accession Nos. AY576553, AY576574, and
AY576577, respectively.
Fig. 2. Kinetics of HCV IRES cleavage by cyanobacterial P RNA. The
HCV BlpI transcript was incubated with increasing amounts of enzyme
(A, lanes 3–5) or at diﬀerent incubation periods (B, lanes 3–5). Lane 1
shows the transcript alone, lane 2, the control reaction in the absence
of ribozyme. (A) The HCV BlpI transcript was incubated with P RNA
for 120 min with 8.4 nM (lane 3), 16.9 nM (lane 4), 33.75 nM (lane 5),
and 67.5 nM (lane 6) of ribozyme. (B) The HCV BlpI transcript was
incubated with 67.5 nM of cyanobacterial P RNA during 60 min (lane
3), 120 min (lane 4), 180 min (lane 5) and 240 min (lane 6).
Fig. 3. Mapping the cleavage site interval in the HCV BlpI RNA transcrip
asymmetrically, 50 end labeled transcript (lanes 1–3), in parallel to another uni
alone, lanes 2 and 5, the control reaction in the absence of ribozyme, and lane
BlpI transcript (1.8 nM) was incubated with the ribozyme for 120 min. (B) R
20% acrylamide-urea electrophoresis. The largest T1 oligonucleotides of Blp
products were identiﬁed by comparison to the band mobility of an interna
known RNase T1 pattern (Piron unpublished). Lanes 1 and 2, uniformly label
Lane 3, RNase T1 complete digestion of the uncut substrate. This pattern
RNA. Lanes 4 and 5 are the ‘‘tracer’’ HCV RNA transcript alone and incub
digestion of ‘‘tracer’’ RNA. It contains the 17-base resistant product 351AAU
50BlpI RNA cleavage product, untreated and completely digested with RN
correspond to the ribozyme 30BlpI RNA cleavage product untreated or compl
contains the 17-base band. Other 14- and 12-base length resistant oligonucleo
the (B) and (C) with ﬁlled boxes. (C) HCV BlpI transcript is represented wit
generated by T1 digestion is shown. The localization of the cleavage produc
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3.1. E. coli P RNA does not cleave HCV RNA
We found that the HCV transcript (1–570) was not cleaved,
under optimal in vitro conditions, by the E. coli ribozyme, as
shown in Fig. 1A. Even when we tried with an excess of ri-
bozyme we obtained identical negative results (data not
shown). Furthermore, the transcript was resistant to cleavage
by E. coli holoenzyme (data not shown).
3.2. Synechocystis P RNA speciﬁcally cleaves an HCV
transcript in vitro
In contrast to the E. coli ribozyme, the Synechocystis ri-
bozyme does not require a CCA sequence at the 30 end of
the pre-tRNA substrate for eﬃcient activity; this sequence
motif is not present in the viral genome [17]. As shown in
Fig. 1B, Synechocystis P RNA cleaved the 570-nt HCV
transcript although with lower eﬃciency than cleavage of
tRNA precursor.
However, a similar amount of an unrelated 400-nt RNA that
is not cleaved by the human enzyme was not aﬀected by the
Synechocystis ribozyme, indicating the speciﬁc nature of the
reaction on the HCV transcript. The ribozyme cleaves the viral
transcript in a single position and yields two products, around
2/3 (larger) and 1/3 (shorter) in length. Fig. 2A shows the directt (1–570). (A) Determination of the cleavage polarity. Cleavage of an
formly labeled transcript (lanes 4–6). Lanes 1 and 4 show the transcript
s 3 and 6, the reaction in the presence of ribozyme (64.5 nM). The HCV
Nase T1 mapping the 50 and 30 fragments products of BlpI RNA in a
I RNA (12–17 bases long) in the uncut RNA or its 50 and 30 fragment
l HCV RNA transcript ‘‘tracer’’, containing bases (A330 to C389) of
ed BlpI transcript alone and incubated in RNase T1 buﬀer, respectively.
contains all the RNase T1-resistant oligonucleotide bands of the BlpI
ated with RNase T1 buﬀer, respectively. Lane 6 is the total RNase T1
CCUAAACCUCAAAG367. Lanes 7 and 8 correspond to the ribozyme
ase T1, respectively. Lane 8 lacks the 17-base band. Lanes 9 and 10
etely digested with RNase T1, respectively. In contrast to lane 8, lane 10
tides could be traced similarly to the 17-base length, as is indicated in
h a black line. The localization of the largest oligonucleotides (boxes)
ed by the ribozyme (Rz) is indicated.
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centage of cleavage. Fig. 2B shows the kinetics of Synecho-
cystis P RNA cleavage of the HCV transcript (1–570), showing
an increasing proportion of cleavage over a 240-min time
course. We notice that diﬀerent preparations of RNase P RNA
of Synechocystis have been used, ones directly after RNA
transcription and puriﬁcation and that folding of the ribozyme
before each experiment is required. These two factors may
explain, at least in part, variations of cleavage eﬃciency be-
tween diﬀerent experiments.
To determine whether the cleavage is maintained in a
larger RNA transcript and to know the polarity of the
cleavage, we assayed three transcripts that were identical at
the 50 end (position 1 of the HCV genome) and progressively
longer at the 30 end (positions AatII: 402, BlpI: 570 and
BamHI: 1360 of the HCV genome, respectively). In the
presence of the ribozyme, the three transcripts rendered one
product of identical length which coincides with the ‘‘larg-
est’’ fragment of the 570-base substrate cleavage reaction and
another of a diﬀerent length in each reaction (data not
shown). We can infer that the ‘‘largest’’ product of identical
size in the three reactions must localize at the 50 end of the
transcripts. A parallel cleavage reaction of the 570-base
transcript uniformly labeled or labeled at the 50 end rendered
a common 2/3 length fragment product, supporting the
proposed polarity of the cleavage (Fig. 3A).Fig. 4. Determination of the cyanobacterial P RNA cleavage site. The reactio
the 30 end (1.8 nM). (A) T1 represents the nuclease partially hydrolyzed size m
to nucleotide positions in the HCV transcript sequence. Rz represents the cle
the right refer to the electrophoretic position of transcripts of known length. (
of the HCV IRES.3.3. Mapping the cyanobacterial RNase P RNA cleavage site in
the HCV IRES
In a ﬁrst attempt to localize more precisely the RNase P
cleavage site, an internally labeled 570-base was digested with
the ribozyme. The uncut substrate as well as the 50 ‘‘largest’’
and 30 ‘‘shortest’’ products were eluted from the gel and sub-
jected to nuclease RNase T1 total digestion. The products of
this reaction were run in 20% polyacrylamide gel in parallel
with a known pattern of RNase T1 products. This pattern was
originated by a total RNase T1 digestion of a transcript cor-
responding to bases 330 to 389 of HCV genome, which covers
the relevant sequence analyzed here (Piron unpublished). We
observed that a ‘‘marker’’ 17-base RNase T1-resistant oligo-
nucleotide (bases 351AAUCCUAAACCUCAAAG367) was
absent from the large 50 fragment but present in the shorter 30
product (Figs. 3 and 4B). This result implies that cleavage is
upstream of position 351 of HCV genome (summarized in
Fig. 3C).
To allow determination of the cleavage site, a 402 nt tran-
script was labeled at the 30 end and incubated with nuclease T1
to give partial digestion. In parallel, this substrate was incu-
bated with the cyanobacterial ribozyme (Fig. 4A). In Fig. 4A,
lane 1, partial digestion of this substrate with nuclease T1
rendered a ladder of oligonucleotides starting at HCV nt
number 402 and ending at every ‘‘G’’ of increasing length. Two
large gaps without RNase T1 sensitive sites could be clearlyn was performed with the HCV AatII transcript (1–402 nts) labeled at
arker. Primary cleavage sites are indicated at the left; the numbers refer
avage reaction with cyanobacterial P RNA (67.5 nM). The numbers at
B) Positioning of the cleavage site on the predicted secondary structure
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quence between positions A369 and G380 followed by the
‘‘marker’’ 17-base resistant sequence A351 to G368. These two
gaps permit to follow the HCV RNase T1 pattern in this re-
gion. In comparison with the RNase T1 pattern, in Fig. 4A,
lane 1, the 30 product of the ribozyme reaction in lane 2 mi-
grated to a position between the fragment ending at G344 and
the next ending at C338. This allows to map the cleavage site
at the interval between 59 and 66 bases away from the 30 end of
the 402 bases fragment (Fig. 4A).
In a secondary structure model of the HCV IRES, cleavage
is localized in domain IV of the HCV IRES and 50 to the AUG
codon (Fig. 4B).
3.4. Synechocystis RNase P RNA cleaves HCV variants
To deﬁne the cleavage by RNase P RNA as a general
property of HCV RNA, three viral sequences obtained from
diﬀerent patients (Fig. 5A), together with the sequence used in
this study (referred to as type 1b here), were compared for
RNase P RNA accessibility (Fig. 5B). We used transcripts
from cloned HCV PCR fragments corresponding to HCVFig. 5. RNase P RNA cleavage of HCV 1–418 RNA variants. (A) Sequence
indicated in bold and underlined. (B) Autoradiogram shows the RNase P RN
RNA. +, presence of the ribozyme in the reaction. The 50 cleavage products
cyanol and bromophenol blue.genome positions 1–418, carrying mutations in the vicinity of
the AUG start codon. Mutations reside within the minimal
RNA fragment which is readily recognized by the human
RNase P enzyme and proposed to be the tRNA-like motif
(Piron, unpublished). Cleavage was consistently observed in all
sequences tested with similar eﬃciencies. The appearance of
two bands probably implies a new secondary cleavage which is
not yet characterized.4. Discussion
This study demonstrates that the RNase P ribozyme from
the cyanobacterium Synechocystis sp. was able to speciﬁcally
cleave the IRES of hepatitis C viral RNA in vitro, whereas the
E. coli enzyme, M1 RNA, was unable to perform this reaction.
M1 catalytic activity is highly dependent on the presence of a
30 CCA terminus on its natural tRNA substrates [15,16], a
sequence motif that is not present in the tRNA-like motif of
the HCV IRES. In contrast, the cyanobacterium ribozyme
does not present this dependence [17] and can eﬀectively cleaveof the HCV variants with mutations between positions 356 and 393 is
A cleavage of three diﬀerent variants: var 1, var 2, var 3 and ‘‘type 1b’’
are indicated by an arrow. XC and B indicate, respectively, the xylene-
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cently determined minimal RNA fragment recognized by hu-
man RNase P (Piron, unpublished results), indicating that the
ribozyme recognizes the same structural RNA motif. Although
this was not a surprising ﬁnding, the fact that the two enzymes
are of very diﬀerent nature–human RNase P is a ribonucleo-
protein composed of RNA and at least nine proteins, and the
Synechocystis RNA moiety is only a ribozyme–supports the
concept that the HCV RNA structure near the AUG is similar
to a tRNA molecule.
It is known that some forms of the catalytic RNA moiety
from E. coli P RNA (either speciﬁcally modiﬁed or selected in
vitro ) can be introduced into mammalian cells for the purpose
of carrying out targeted cleavage of mRNA molecules. In this
sense, the Synechocystis ribozyme might be a candidate tool
for inactivation of HCV RNA within the cell. This strategy is
supported by the assumption that viral RNA is not a natural
substrate for endogenous human RNase P activity. This as-
sumption is, in turn, based on several observations that argue
against an active role of endogenous RNase P cleavage in
HCV biology: the presence of HCV RNA in the nucleus
(where most RNase P is found) has never been demonstrated
[18] and no evidence of subgenomic HCV RNAs has been
reported [19].
In previous studies, the IRES portion of HCV RNA has
been considered a target region for inactivating HCV with the
use of nucleic acids, including complementary oligonucleo-
tides, ribozymes and aptamers [5]. There are two reasons for
this: (1) Cleavage within the viral IRES should, in theory,
eliminate translation of the polyprotein; hence, no individual
proteins should be produced. (2) The 50 UTR sequence is the
most conserved among diﬀerent viral isolates. However, re-
garding this second argument, ﬁne analysis of the sequence
composition of the virus population within single viral isolates
has demonstrated that variants carrying single and double
mutations are frequent, and that these might be responsible for
viral evasion of treatment when positive selection pressure is
introduced with an antigenomic agent. Recognition of struc-
tures instead of sequences may represent a great advantage in
the ﬁght against the highly variable HCV. As an indicative of
the requisite for conservation of this structural motif is the fact
that it is conserved even in HCV-related pestiviruses, classic
swine fever virus, bovine diarrhea virus and border disease
virus [2] because it is implicated in HCV IRES function [20,21].
In fact, several sequences with point mutations in the HCV
IRES tRNA-like motif obtained from infected patients show
similar sensitivity to synechocystis sp. ribozyme.
Although the activity of the natural Synechocystis ribozyme
is low, methods including in vitro selection of mutated variants
or engineered molecules can be set up to increase its antiviral
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